• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    A Subcutaneously Administered Investigational RNAi Therapeutic, Fitusiran (ALN-AT3), Targeting Antithrombin for Treatment of Hemophilia: Interim Results in Patients with Hemophilia A or B 
    •   QMRO Home
    • Blizard Institute
    • Centre for Immunobiology
    • A Subcutaneously Administered Investigational RNAi Therapeutic, Fitusiran (ALN-AT3), Targeting Antithrombin for Treatment of Hemophilia: Interim Results in Patients with Hemophilia A or B
    •   QMRO Home
    • Blizard Institute
    • Centre for Immunobiology
    • A Subcutaneously Administered Investigational RNAi Therapeutic, Fitusiran (ALN-AT3), Targeting Antithrombin for Treatment of Hemophilia: Interim Results in Patients with Hemophilia A or B
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.